

Special Issue

Emerging Trends in Personalized Medicine in COVID-19

Message from the Guest Editor

Dear colleagues, Personalized medicine is an emerging approach for effectiveness in treatment outcomes and toxicity for each COVID-19 patient. Autologous blood plasma and peripheral blood stem cells are a possible treatment for fulminant COVID-19 infection. Personalization has the potential to tailor therapy towards the pharmacogenomics, immunology and immunology genetics drivers of treatment outcome, and thus, on patients' quality of life. Furthermore, this could be the key to avoiding suboptimal drug dosing or adverse events, taking into account the genetic variability of each person, their sex and their age. This Special Issue, "Emerging Trends in Personalized Medicine in COVID-19", will focus on personalized treatment in COVID-19 and long COVID research, including clinical, preclinical, pharmacological and translational trends. Dr. Kieu C.D. Nguyễn

Guest Editor

Prof. Dr. Kieu C. D. Nguyễn

Department of Interdisciplinary Medicine, School of Medicine,
University of Bari "Aldo Moro", 70124 Bari, Italy

Deadline for manuscript submissions

closed (31 October 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/162674

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).